| Phase 13 trials |
|
Phase 1
|
NCT03358719 |
Mar 2018 → Feb 2020 |
acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome |
Roswell Park Cancer Institute |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01834248 |
Jul 2013 → Jun 2015 |
acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent, chronic myelomonocytic leukemia, refractory anemia with excess blasts in transformation |
Roswell Park Cancer Institute |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01522820 |
Mar 2012 → Jul 2016 |
anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, brain neoplasm +19 |
Roswell Park Cancer Institute |
Completed
|
No outcome recorded
|
| Phase 1/25 trials · 1 missed |
|
Phase 1/2
|
NCT03206047 |
Nov 2017 → Nov 2020 |
fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT02661100 |
Jan 2017 → Jul 2018 |
melanoma, mesothelioma, non-small cell lung carcinoma, small cell lung carcinoma +2 |
Case Comprehensive Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT02413827 |
Apr 2015 → Nov 2016 |
metastatic melanoma |
Celldex Therapeutics |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT02166905 |
Oct 2014 → Aug 2020 |
fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma |
Roswell Park Cancer Institute |
Completed
|
Missed primary
|
|
Phase 1/2
|
NCT00948961 |
Sep 2009 → Jun 2012 |
cancer |
Celldex Therapeutics |
Completed
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT02495636 |
Jul 2015 → Jul 2017 |
non-small cell lung carcinoma |
Yale University |
Withdrawn
|
No outcome recorded
Stop: Enrollment |
|
Phase 2
|
NCT02129075 |
Apr 2014 → Mar 2016 |
cutaneous melanoma, mucosal melanoma, ocular melanoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|